Conjugated estrogens vaginal - Teva

Drug Profile

Conjugated estrogens vaginal - Teva

Alternative Names: Bijuva; SCE A

Latest Information Update: 15 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barr Laboratories
  • Developer Teva Pharmaceutical Industries
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis

Most Recent Events

  • 01 Dec 2008 Registered for Vaginal atrophy in USA (Vaginal)
  • 26 Apr 2005 Duramed Pharmaceuticals has received a non-approvable letter from the US FDA for Bijuva™ in Vaginal atrophy
  • 04 Nov 2004 Preregistration for Vaginal atrophy in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top